Takeda Pharmaceutical Income from Discontinued Operations 2010-2024 | TAK

Takeda Pharmaceutical annual/quarterly income from discontinued operations history and growth rate from 2010 to 2024. Income from discontinued operations can be defined as income or loss from the complete discontinuation of a segment or business, net of associated taxes and fees.
  • Takeda Pharmaceutical income from discontinued operations for the quarter ending June 30, 2024 was $M, a NAN% increase year-over-year.
  • Takeda Pharmaceutical income from discontinued operations for the twelve months ending June 30, 2024 was $0M, a NAN% increase year-over-year.
  • Takeda Pharmaceutical annual income from discontinued operations for 2024 was $0B, a NAN% decline from 2023.
  • Takeda Pharmaceutical annual income from discontinued operations for 2023 was $0B, a NAN% decline from 2022.
  • Takeda Pharmaceutical annual income from discontinued operations for 2022 was $0B, a NAN% decline from 2021.
Takeda Pharmaceutical Annual Income from Discontinued Operations
(Millions of US $)
2024 $
2023 $
2022 $
2021 $
2020 $
2019 $
2018 $
2017 $
2016 $
2015 $
2014 $
2013 $0
2012 $0
2011 $0
2010 $0
2009 $
Takeda Pharmaceutical Quarterly Income from Discontinued Operations
(Millions of US $)
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31
2019-12-31
2019-09-30
2019-06-30
2018-12-31
2018-06-30
2017-06-30
2016-06-30
2015-06-30
2015-03-31 $0
2014-12-31 $0
2014-09-30 $0
2014-06-30 $0
2014-03-31 $0
2013-12-31 $0
2013-09-30 $0
2013-06-30 $0
2013-03-31 $-392
2012-12-31 $-32
2012-09-30 $98
2012-06-30 $121
2012-03-31 $-448
2011-12-31 $0
2011-09-30 $0
2011-03-31 $0
2010-03-31 $0
2009-09-30 $0
2009-03-31 $0
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $43.878B $28.196B
Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company, engaged in manufacturing, marketing, and importing/exporting pharmaceutical drugs. Takeda's core business comprise of ethical drugs and its portfolio includes lansoprazole for the treatment of peptic ulcers, leuprolide acetate for the treatment of prostate cancer and endometriosis, pioglitazone hydrocholoride for the treatment of diabetes, and candesartan cilexetil for the treatment of hypertension. The Company promotes enhancing R&D pipeline, while concentrating its management resources to the four core therapeutic areas: lifestyle-related diseases, oncology and urological diseases, central nervous system disease and gastroenterological diseases. It operates in two segments- Ethical drug business and Consumer healthcare business. Consumer healthcare business provides Alinamin (vitamin B1 derivative preparations, etc.), Benza (cold remedies). Takeda Pharmaceutical Company Limited is headquartered in Osaka, Japan.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $76.865B 29.58
Merck (MKKGY) Germany $20.789B 22.69
Astellas Pharma (ALPMY) Japan $20.214B 18.62
Sandoz Group AG (SDZNY) Switzerland $19.585B 0.00
United Therapeutics (UTHR) United States $17.746B 17.46
Summit Therapeutics (SMMT) United States $15.405B 0.00
Neurocrine Biosciences (NBIX) United States $12.686B 33.59
Shionogi (SGIOY) Japan $12.330B 11.81
Catalent (CTLT) United States $10.882B 0.00
Madrigal Pharmaceuticals (MDGL) United States $7.377B 0.00
Jazz Pharmaceuticals (JAZZ) Ireland $6.889B 6.60
Orion OYJ (ORINY) Finland $6.848B 19.25
Ionis Pharmaceuticals (IONS) United States $5.708B 0.00
Corcept Therapeutics (CORT) United States $5.682B 43.04
Crinetics Pharmaceuticals (CRNX) United States $4.735B 0.00
PTC Therapeutics (PTCT) United States $3.322B 0.00
Dyne Therapeutics (DYN) United States $2.993B 0.00
Catalyst Pharmaceuticals (CPRX) United States $2.695B 12.28
Arrowhead Pharmaceuticals (ARWR) United States $2.653B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $2.631B 15.18
Soleno Therapeutics (SLNO) United States $2.210B 0.00
NewAmsterdam Pharma (NAMS) Netherlands $1.961B 0.00
Recursion Pharmaceuticals (RXRX) United States $1.959B 0.00
Centessa Pharmaceuticals (CNTA) United Kingdom $1.812B 0.00
Harrow (HROW) United States $1.712B 0.00
Ocular Therapeutix (OCUL) United States $1.706B 0.00
BioCryst Pharmaceuticals (BCRX) United States $1.601B 0.00
Xencor (XNCR) United States $1.586B 0.00
Ardelyx (ARDX) United States $1.537B 0.00
ARS Pharmaceuticals (SPRY) United States $1.524B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $1.473B 0.00
Enliven Therapeutics (ELVN) United States $1.396B 0.00
Evotec AG (EVO) Germany $1.370B 0.00
Indivior (INDV) United States $1.282B 5.22
Cassava Sciences (SAVA) United States $1.275B 0.00
Guardian Pharmacy Services (GRDN) United States $1.249B 0.00
Collegium Pharmaceutical (COLL) United States $1.111B 6.38
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.075B 0.00
Bioventus (BVS) United States $0.913B 28.92
Relay Therapeutics (RLAY) United States $0.837B 0.00
Ironwood Pharmaceuticals (IRWD) United States $0.805B 50.40
Cronos Group (CRON) Canada $0.784B 0.00
USANA Health Sciences (USNA) United States $0.769B 14.25
Tourmaline Bio (TRML) United States $0.703B 0.00
Exscientia (EXAI) United Kingdom $0.642B 0.00
Savara (SVRA) United States $0.629B 0.00
Korro Bio (KRRO) United States $0.620B 0.00
Siga Technologies (SIGA) United States $0.551B 6.60
Elite Pharmaceuticals (ELTP) United States $0.550B 51.50
OmniAb (OABI) United States $0.549B 0.00
Verve Therapeutics (VERV) United States $0.543B 0.00
Silence Therapeutics (SLN) United Kingdom $0.538B 0.00
ProKidney (PROK) United States $0.530B 0.00
Larimar Therapeutics (LRMR) United States $0.521B 0.00
Altimmune (ALT) United States $0.520B 0.00
Xeris Biopharma Holdings (XERS) United States $0.498B 0.00
KalVista Pharmaceuticals (KALV) United States $0.493B 0.00
Zevra Therapeutics (ZVRA) United States $0.464B 0.00
Aquestive Therapeutics (AQST) United States $0.462B 0.00
4D Molecular Therapeutics (FDMT) United States $0.434B 0.00
Esperion Therapeutics (ESPR) United States $0.434B 0.00
Theravance Biopharma (TBPH) Cayman Islands $0.426B 0.00
Organogenesis (ORGO) United States $0.426B 0.00
Amylyx Pharmaceuticals (AMLX) United States $0.423B 0.00
Akebia Therapeutics (AKBA) United States $0.421B 0.00
Lyell Immunopharma (LYEL) United States $0.379B 0.00
Sage Therapeutics (SAGE) United States $0.364B 0.00
Aldeyra Therapeutics (ALDX) United States $0.321B 0.00
Avita Medical (RCEL) United States $0.317B 0.00
Heron Therapeutics (HRTX) United States $0.273B 0.00
Lexeo Therapeutics (LXEO) United States $0.271B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.265B 0.00
Nature's Sunshine Products (NATR) United States $0.263B 18.00
Acrivon Therapeutics (ACRV) United States $0.259B 0.00
Nektar Therapeutics (NKTR) United States $0.256B 0.00
Enanta Pharmaceuticals (ENTA) United States $0.244B 0.00
Pyxis Oncology (PYXS) United States $0.239B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.228B 0.00
Profound Medical (PROF) Canada $0.197B 0.00
Nanobiotix S.A (NBTX) France $0.195B 0.00
MediWound (MDWD) Israel $0.193B 0.00
Innate Pharma SA (IPHYF) France $0.180B 0.00
Achieve Life Sciences (ACHV) Canada $0.176B 0.00
Galectin Therapeutics (GALT) United States $0.175B 0.00
Context Therapeutics (CNTX) United States $0.167B 0.00
Aclaris Therapeutics (ACRS) United States $0.161B 0.00
CytoDyn (CYDY) United States $0.155B 0.00
Cardiol Therapeutics (CRDL) Canada $0.154B 0.00
Incannex Healthcare (IXHL) Australia $0.144B 0.00
Telomir Pharmaceuticals (TELO) United States $0.136B 0.00
VAXART, INC (VXRT) United States $0.125B 0.00
Century Therapeutics (IPSC) United States $0.118B 0.00
AlloVir (ALVR) United States $0.117B 0.00
Fractyl Health (GUTS) United States $0.116B 0.00
Journey Medical (DERM) United States $0.113B 0.00
Karyopharm Therapeutics (KPTI) United States $0.111B 0.00
OptiNose (OPTN) United States $0.107B 0.00
Relmada Therapeutics (RLMD) United States $0.103B 0.00
Regulus Therapeutics (RGLS) United States $0.099B 0.00
Assertio Holdings (ASRT) United States $0.095B 16.67
Arch Biopartners (ACHFF) Canada $0.092B 0.00
CASI Pharmaceuticals (CASI) China $0.089B 0.00
PMV Pharmaceuticals (PMVP) United States $0.086B 0.00
Metagenomi (MGX) United States $0.080B 0.00
ElectroCore (ECOR) United States $0.078B 0.00
ESSA Pharma (EPIX) Canada $0.076B 0.00
Swiftmerge Acquisition (IVCP) United States $0.076B 368.67
Prelude Therapeutics (PRLD) United States $0.073B 0.00
Vivani Medical (VANI) United States $0.070B 0.00
Inotiv (NOTV) United States $0.063B 0.00
Nutriband (NTRB) United States $0.063B 0.00
Citius Pharmaceuticals (CTXR) United States $0.063B 0.00
Gain Therapeutics (GANX) United States $0.058B 0.00
Champions Oncology (CSBR) United States $0.058B 0.00
Mural Oncology (MURA) Ireland $0.057B 0.00
Qilian Holding Group (BGM) China $0.054B 0.00
Protara Therapeutics (TARA) United States $0.051B 0.00
SCYNEXIS (SCYX) United States $0.050B 0.00
Unicycive Therapeutics (UNCY) United States $0.047B 0.00
Rafael Holdings (RFL) United States $0.047B 0.00
VYNE Therapeutics (VYNE) United States $0.046B 0.00
Carisma Therapeutics (CARM) United States $0.046B 0.00
DURECT (DRRX) United States $0.042B 0.00
ProPhase Labs (PRPH) United States $0.037B 0.00
BioLineRx (BLRX) Israel $0.036B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.034B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.034B 0.00
Oruka Therapeutics (ORKA) United States $0.033B 0.00
Surrozen (SRZN) United States $0.033B 0.00
Lipocine (LPCN) United States $0.032B 0.00
Reviva Pharmaceuticals Holdings (RVPH) United States $0.031B 0.00
FibroGen (FGEN) United States $0.031B 0.00
Natural Alternatives (NAII) United States $0.028B 0.00
Iterum Therapeutics (ITRM) Ireland $0.028B 0.00
Enlivex Therapeutics (ENLV) Israel $0.027B 0.00
Tempest Therapeutics (TPST) United States $0.026B 0.00
GlycoMimetics (GLYC) United States $0.024B 0.00
BioVie (BIVI) United States $0.023B 0.00
MEI Pharma (MEIP) United States $0.020B 0.71
Inhibikase Therapeutics (IKT) United States $0.020B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.019B 0.00
Marinus Pharmaceuticals (MRNS) United States $0.018B 0.00
Lyra Therapeutics (LYRA) United States $0.018B 0.00
TherapeuticsMD (TXMD) United States $0.018B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.017B 0.00
PolyPid (PYPD) Israel $0.016B 0.00
Minerva Neurosciences (NERV) United States $0.016B 0.00
Cosmos Health (COSM) United States $0.016B 0.00
NLS Pharmaceutics (NLSP) Switzerland $0.016B 0.00
Mannatech (MTEX) United States $0.016B 0.00
Talphera (TLPH) United States $0.015B 0.00
Nuvilex (PMCB) United States $0.014B 0.00
Scienture Holdings (SCNX) United States $0.014B 0.00
NRx Pharmaceuticals (NRXP) United States $0.014B 0.00
Avalo Therapeutics (AVTX) United States $0.014B 0.00
Vivos Therapeutics (VVOS) United States $0.013B 0.00
Indaptus Therapeutics (INDP) United States $0.012B 0.00
Addex Therapeutics (ADXN) Switzerland $0.012B 0.00
CERo Therapeutics Holdings (CERO) United States $0.011B 0.00
Dominari Holdings (DOMH) United States $0.011B 0.00
Redhill Biopharma (RDHL) Israel $0.011B 0.00
Kiora Pharmaceuticals (KPRX) United States $0.010B 0.00
Conduit Pharmaceuticals (CDT) United States $0.010B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.010B 0.00
Jaguar Animal Health (JAGX) United States $0.010B 0.00
Traws Pharma (TRAW) United States $0.009B 0.00
Plus Therapeutics (PSTV) United States $0.008B 0.00
TransCode Therapeutics (RNAZ) United States $0.008B 0.00
Viracta Therapeutics (VIRX) United States $0.008B 0.00
Aptorum Group (APM) United Kingdom $0.007B 0.00
Klotho Neurosciences (KLTO) United States $0.007B 0.00
Biomerica (BMRA) United States $0.006B 0.00
Xenetic Biosciences (XBIO) United States $0.006B 0.00
Oncternal Therapeutics (ONCT) United States $0.005B 0.00
SHINECO (SISI) China $0.005B 0.00
Mangoceuticals (MGRX) United States $0.005B 0.00
Ainos (AIMD) United States $0.004B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.004B 0.00
Heatwurx (PCSA) United States $0.004B 0.00
TNF Pharmaceuticals (TNFA) United States $0.004B 0.00
Alaunos Therapeutics (TCRT) United States $0.003B 0.00
Petros Pharmaceuticals (PTPI) United States $0.003B 0.00
Avenue Therapeutics (ATXI) United States $0.003B 0.09
InMed Pharmaceuticals (INM) Canada $0.003B 0.00
XORTX Therapeutics (XRTX) Canada $0.003B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.003B 0.00
Phio Pharmaceuticals (PHIO) United States $0.003B 0.00
Molecular Templates (MTEM) United States $0.003B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.003B 0.00
SciSparc (SPRC) Israel $0.002B 0.00
Clearmind Medicine (CMND) Canada $0.002B 0.00
Bio-Path Holdings (BPTH) United States $0.002B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.002B 0.00
Aditxt (ADTX) United States $0.002B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.002B 0.00
China SXT Pharmaceuticals (SXTC) China $0.002B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.002B 0.00
Altamira Therapeutics (CYTO) Bermuda $0.002B 0.00
Qualigen Therapeutics (QLGN) United States $0.001B 0.00
Universe Pharmaceuticals INC (UPC) China $0.001B 0.00
PainReform (PRFX) Israel $0.000B 0.00
Grifols, S.A (GRFS) Spain $0.000B 0.00
4D Pharma (LBPS) United Kingdom $0.000B 0.00
Procaps Group, S.A (PROC) Luxembourg $0.000B 3.27
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00
Stevanato Group S.p.A (STVN) Italy $0.000B 44.22